Advisor Group Inc. trimmed its holdings in shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 7.3% during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 7,513 shares of the medical equipment provider’s stock after selling 595 shares during the period. Advisor Group Inc.’s holdings in Zimmer Biomet Holdings were worth $879,000 as of its most recent filing with the Securities and Exchange Commission.

Other large investors have also bought and sold shares of the company. Bronfman E.L. Rothschild L.P. raised its position in Zimmer Biomet Holdings by 25.3% during the second quarter. Bronfman E.L. Rothschild L.P. now owns 827 shares of the medical equipment provider’s stock valued at $106,000 after buying an additional 167 shares during the period. Parkside Financial Bank & Trust increased its position in Zimmer Biomet Holdings by 3.9% in the 2nd quarter. Parkside Financial Bank & Trust now owns 872 shares of the medical equipment provider’s stock worth $112,000 after purchasing an additional 33 shares during the last quarter. BB&T Investment Services Inc. acquired a new position in Zimmer Biomet Holdings in the 2nd quarter worth about $144,000. Sandy Spring Bank increased its position in Zimmer Biomet Holdings by 5.4% in the 2nd quarter. Sandy Spring Bank now owns 1,288 shares of the medical equipment provider’s stock worth $166,000 after purchasing an additional 66 shares during the last quarter. Finally, Grove Bank & Trust increased its position in Zimmer Biomet Holdings by 346.1% in the 2nd quarter. Grove Bank & Trust now owns 1,316 shares of the medical equipment provider’s stock worth $169,000 after purchasing an additional 1,021 shares during the last quarter. 85.36% of the stock is currently owned by hedge funds and other institutional investors.

Several brokerages have weighed in on ZBH. Zacks Investment Research lowered Zimmer Biomet Holdings from a “hold” rating to a “strong sell” rating in a research report on Monday. Deutsche Bank AG raised Zimmer Biomet Holdings from a “hold” rating to a “buy” rating and set a $128.00 target price on the stock in a research report on Tuesday, November 14th. Edward Jones raised Zimmer Biomet Holdings from a “hold” rating to a “buy” rating in a report on Thursday, November 9th. Royal Bank Of Canada lowered their price objective on Zimmer Biomet Holdings to $125.00 and set an “outperform” rating on the stock in a report on Tuesday, November 7th. Finally, Stifel Nicolaus reissued a “hold” rating and set a $120.00 price objective on shares of Zimmer Biomet Holdings in a report on Friday, November 3rd. Four equities research analysts have rated the stock with a sell rating, seven have issued a hold rating, fourteen have issued a buy rating and one has given a strong buy rating to the company’s stock. The stock currently has a consensus rating of “Hold” and a consensus price target of $133.71.

COPYRIGHT VIOLATION NOTICE: This story was originally published by TheOlympiaReport and is owned by of TheOlympiaReport. If you are reading this story on another domain, it was illegally copied and reposted in violation of US & international copyright law. The legal version of this story can be read at https://theolympiareport.com/2017/11/22/zimmer-biomet-holdings-inc-zbh-position-trimmed-by-advisor-group-inc.html.

Shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH) opened at $113.56 on Wednesday. Zimmer Biomet Holdings, Inc. has a twelve month low of $98.20 and a twelve month high of $133.49. The firm has a market capitalization of $22,713.43, a price-to-earnings ratio of 13.90, a P/E/G ratio of 1.74 and a beta of 1.17. The company has a current ratio of 1.47, a quick ratio of 0.78 and a debt-to-equity ratio of 0.88.

Zimmer Biomet Holdings (NYSE:ZBH) last released its quarterly earnings results on Wednesday, November 1st. The medical equipment provider reported $1.72 earnings per share for the quarter, missing the Zacks’ consensus estimate of $1.74 by ($0.02). The business had revenue of $1.82 billion for the quarter, compared to analyst estimates of $1.83 billion. Zimmer Biomet Holdings had a net margin of 8.36% and a return on equity of 16.29%. The company’s revenue for the quarter was down .8% on a year-over-year basis. During the same period in the prior year, the business earned $1.79 earnings per share. equities analysts anticipate that Zimmer Biomet Holdings, Inc. will post 8.03 earnings per share for the current fiscal year.

Zimmer Biomet Holdings Profile

Zimmer Biomet Holdings, Inc is engaged in designing, manufacturing and marketing of orthopedic reconstructive products; sports medicine, biologics, extremities and trauma products; office-based technologies; spine, craniomaxillofacial and thoracic products; dental implants, and related surgical products.

Want to see what other hedge funds are holding ZBH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Zimmer Biomet Holdings, Inc. (NYSE:ZBH).

Institutional Ownership by Quarter for Zimmer Biomet Holdings (NYSE:ZBH)

Receive News & Ratings for Zimmer Biomet Holdings Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zimmer Biomet Holdings Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.